By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

A federal judge ordered CVS Health's pharmacy benefit manager unit to pay $289.9 million in damages and penalties after it ...

Penn North Plaza is a symbol of the city’s struggles: a nondescript, six-story apartment building where at least 62 ...

Caremark was found liable in June, and Philadelphia federal court Chief Judge Mitchell Goldberg ordered the company to pay ...

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.

CVS Health stock offers an above-average dividend yield for investors seeking income and it's run up to a new buy point.

CVS Health (CVS) stock in focus as its pharmacy benefit manager CVS Caremark faces $289.9M in damages and penalties for ...

A Pennsylvania judge has ordered CVS to pay $289 million in damages as part of a long-running whistleblower case. | A ...

A federal judge has ordered CVS Caremark to pay nearly $290 million in damages after determining the pharmacy benefit manager overbilled Medicare for prescription drugs, according to court documents ...

Is August too early to get this year’s influenza vaccine? Here’s when and where flu shots are available and when the CDC recommends getting one.

"Two children are gone, two families are shattered, and it never should have happened,” said Marion County Prosecutor Ryan ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...